Parexel and Eli Lilly are launching a clinical research learning and development program in China as recent reforms have “dramatically” increased the need for new sites in the country.
The new “groundbreaking” model can translate the results of mouse experiments into the equivalent human condition, outperforming traditional methods of extrapolation by up to 50%, say researchers.
PPD is adding nearly 6,000 square feet of new lab space – and about 20 employees – dedicated to gene and cell therapy analytical testing at its site in Athlone, Ireland.
The digital patient recruitment and engagement company has released its new digital solutions to build long-term relationships with clients, sponsors, and CROs.
The information analytics business Elsevier has launched a new cloud-based data platform, Entellect, to de-silo, contextualize, and connect drug, target, and disease data.
Medidata’s machine learning-based solution revealed novel biomarkers for Castleman disease among other discoveries that could help accelerate diagnosis and treatment.
A lobby group has filed a complaint alleging illegal discrimination by airlines refusing to transport lab animals – a battle that will be difficult to win, says an industry expert.
SPARC and Schrödinger will collaborate to use Schrödinger’s technological platforms and SPARC’s insights into research therapeutics for neurodegenerative conditions.
ARG has made the move across the Atlantic, establishing its first office outside of the US following its acquisition of the UK-based CRO CCA Clinical Research.
In the era of big data, the industry is working to address the ethical concerns of integrating patient information into the health care landscape – though a key challenge will be reaching a consensus on what constitutes reliable evidence.
The clinical-stage gene therapy company Voyager Therapeutics has entered into collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to expand its manufacturing capabilities.
By Melanie Brickman Borchard, PhD, MSc, director of life sciences, New York Academy of Sciences
Increased access to real-world data sources opens up new possibilities, but it also raises new ethical questions, which cannot be tackled by one organization, government agency, or company alone.
Mylan has requested all lots of valsartan, as well as combination amlodipine/valsartan, and valsartan/ hydrochlorothiazide tablets, be returned in the US.
The US FDA’s New Inspection Protocol Project represents an “improvement process step” towards a risk-based site selection model, according to the Swedish CDMO.
The FDA recently released open source code and technical documents for its new mobile app – MyStudies – which is designed to collect information about medication use, health system touchpoints, and patient-reported outcomes.
Litmus Health’s profile of the wearables market names the top 15 devices today available to researchers incorporating real-life data into studies and trials – with a focus on data quality and transparency.
Biovation expands its technology portfolio with all-encompassing tableting equipment to grow its production capacity and change specifications ‘on the fly’.
Unilever will acquire GlaxoSmithKline’s Health Food Drinks portfolio in Asia for €3.3bn ($3.8bn): a move that will boost its presence in the Indian market.
The Asia-Pacific CRO Novotech has grown its operations in South Korea, a market that has seen greater interest from North American and European companies, says exec.
The US Court of Appeals for the Federal Circuit removed the injunction against Dr. Reddy’s, which prevented the company from selling its Suboxone generic.
The colour of a capsule can play an important role in the safety of a product and provide consumers with intuitive information for dosage, according to Nicolas Madit of Lonza.
ABL named a successor to its previous CEO, Syneos has two new hires, and BTS Research appointed a VP to push its growth model. These, among other people on the move this month.
Bayer looks to boost investor confidence by cutting away its animal health unit, selected consumer health brands and a number of jobs to focus on its life sciences businesses.
If the industry wants to maintain control of manufacturing operations, it has to adopt digital technologies or face being ousted by Amazon, suggested GSK’s Pharma 4.0 director.
Catalent’s existing clinical packaging facility in Shanghai is nearing the end of its expansion, ready to meet the needs of the growing Asia-Pacific region.
Novartis has announced plans to move its UK headquarters to an ‘emerging life sciences cluster’ in West London, 50 minutes’ drive from its current location in Surrey.
PRA Health Sciences has launched a new site network focused on improving pediatric clinical development and access to novel medicines in this special patient population.
Evotec and Immuneering are combining iPSC and AI technologies through a research collaboration to discover novel small molecules for rare hereditary metabolic diseases.
GW Pharma has told investors its capacity is “more than sufficient” to meet launch requirements in Europe next year, where the firm’s CBD medicine Epidiolex is under review.
The new recommendations look to provide a more efficient and effective means of qualifying clinical trial investigators – to help teams ‘conduct better, more efficient clinical trials,’ says CTTI exec.
